Nurix Therapeutics

Q2 FY2026 EarningsQ2 FY26 missed consensus on both top and bottom lines: revenue of $9.0M fell significantly short of the $15.3M expected, while GAAP EPS of -$0.81 missed the -$0.73 consensus. Higher R&D costs ($87.7M) driven by clinical trial acceleration further pressured margins. However, the newly announced global collaboration with Roche, featuring a $700M upfront payment expected in Q3, provides a massive pro-forma cash cushion of ~$1.14B and validates the bexobrutideg platform.